Ffective Temperament and Seasonality in Bipolar Disorder

Altınbaş, Kürşat; Ince, Bahri; Gülöksüz, Sinan

doi:10.24869/psyd.2019.106

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our sample consisted of 503 (71%) patients with BDI and 205 (29%) with BDII ( Table 1). Of all patients, 16.5% (N = 117) fulfilled DSM-5 seasonal pattern criteria and 13.5% (N = 96) fulfilled DSM-IV-TR criteria ( Table 1). The sample was further divided according to DSM-5 seasonality into two groups: without and with seasonality ( Table 2).…”

Section: Resultsmentioning

confidence: 99%

“…11 Indeed, seasonality is associated with a positive family history of BD 12 and it also shows heritability in twin studies. 13,14 Several mechanisms might underlie seasonality, involving photoperiod and sunlight exposure, 15 temperament, 16 chronotype, 17 and gender. 18 Globally, the clinical correlates of seasonality broadly point toward a more severe clinical profile.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical correlates of seasonality in bipolar disorder: A specifier that needs specification?

Fico

Toffol

Anmella

et al. 2020

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective Seasonal pattern (SP) is a bipolar disorder (BD) specifier that indicates a tendency towards affective relapses during specific moments of the year. SP affects 15%–25% of BD patients. In the past, SP was applied only to depressive relapses while, in DSM‐5, SP may be applied to both depressive and (hypo)manic episodes. We examined the association between different clinical correlates of BD and SP according to its current definition in a cohort of patients with BD type I (BDI) and II (BDII). Methods Patients were recruited from a specialized unit and assessed according to the season of relapse and type of episode per season. SP and non‐SP patients were compared looking into sociodemographic and clinical correlates. Significant variables at univariate comparisons were included in multivariate logistic regression with SP as the dependent variable. Results 708 patients were enrolled (503 BDI, 205 BDII), and 117 (16.5%) fulfilled DSM‐5 criteria for SP. The mean age was 45.3 years (SD = 14.18), and 389 were female (54.9%). The logistic regression model included a significant contribution of BDII (OR = 2.23, CI 1.4–3.55), family history of mood disorder (OR = 1.97, CI 1.29–3.01), undetermined predominant polarity (OR = 0.44, CI 0.28–0.70), and aggressive behavior (OR = 0.42, CI 0.23–0.75). Conclusion Our results outline a novel positive association of SP with undetermined predominant polarity, BDII, family history of mood disorder, and with fewer aggressiveness‐related symptoms. Seasonality is associated with a biphasic pattern with similar dominance of (hypo)mania and depression and is more frequent in BDII as compared to BDI. Seasonal episodes may be easier to predict, but difficult to prevent.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical correlates of seasonality in bipolar disorder: A specifier that needs specification?

Fico

Toffol

Anmella

et al. 2020

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Insomnia, akathisia, constipation, anxiety, nausea and vomiting are reported to occur with cariprazine treatment in patients with negative symptoms of schizophrenia ( Table 3 ). However, the side effects have lower occurrence rate than other available SGAs ( 86 ). Discontinuation of cariprazine due to treatment-emergent adverse events is as low as 9% ( 62 ).…”

Section: Cariprazine: a Novel Third Generation Antipsychoticmentioning

confidence: 97%

A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

Selvan,

Devkare,

Shetty

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

Management of negative symptoms is one of the most challenging and important unmet needs of schizophrenia treatment. Negative symptoms together with positive symptoms result in significant psychosocial impairment and poor quality of life. Existing studies on atypical antipsychotics reported limited treatment adherence due to higher prevalence of treatment-emergent adverse events, such as diabetes, weight gain, hyperlipidemia, hyperprolactinemia and hypertension. A compound with greater affinity for dopamine D2/D3 receptors may improve negative symptoms, mood, and cognitive impairment associated with schizophrenia. In 2015, the US FDA has approved cariprazine, a partial D2/D3 agonist for treatment of schizophrenia, mania or mixed episodes. Midlands and Lancashire Commissioning Support Unit, UK (2019) has particularly suggested cariprazine for the treatment of predominant negative symptoms of schizophrenia. India’s Central Drugs Standard Control Organization (CDSCO) has approved cariprazine in 2021 for the treatment of schizophrenia, manic or mixed episodes associated with bipolar I disorder. A ten-fold greater affinity for D3 receptors and partial agonism to serotonin receptors, along with longer half-life make cariprazine distinct when compared with other atypical antipsychotics. Cariprazine is also reported to have fewer incidents of metabolic and hormonal adverse events, and has been shown to provide better relapse prevention. Recent evidence indicates promising effect of cariprazine in ameliorating negative symptoms as well as psychotic symptoms in patients with schizophrenia. In addition, improved adherence to treatment (adjunctive/monotherapy) with cariprazine in patients having inadequate response to an ongoing antipsychotic treatment has also been clinically established. This review presents the evidence-based safety and efficacy of cariprazine for treatment of predominant negative symptoms of schizophrenia.

show abstract

“…Several studies have focused on temperament assessments in individuals diagnosed with MDD [15][16][17] or with BD specifically [18][19][20][21][22][23][24], or have considered mood disorders together using TCI [25,26] or TEMPS [1,[27][28][29][30]. Such studies have revealed differences between mood disorder patients and controls, including unaffected family members, with suggestive differences between BD and MDD patients and possibly between BD-1 and BD-2 patients based on ratings of cyclothymic, hyperthymic, and irritable temperaments, in particular, as well as ratings of harm-avoidance [1,[31][32][33].…”

Section: Introductionmentioning

confidence: 99%

Relationships of affective temperament ratings to diagnosis and morbidity measures in major affective disorders

Miola

Baldessarini

Pinna³

et al. 2021

Eur. Psychiatr.

View full text Add to dashboard Cite

Background. Ratings of affective temperament types show promise in helping to differentiate diagnostic groups among major affective disorders as well as to predict associations with important aspects of morbidity including suicidal risk. Methods. The Temperament Evaluation of Memphis, Pisa, Paris, and San Diego auto-rating (TEMPS-A) questionnaire was completed by 858 unselected, consecutive, consenting adults diagnosed with a DSM-5 major affective disorder (173 bipolar-1 [BD-1]), 250 BD-2, 435 major depressive disorder [MDD]) to score for anxious (anx), cyclothymic (cyc), dysthymic (dys), hyperthymic (hyp), and irritable (irr) affective temperaments. We tested their associations with diagnosis and selected clinical factors, including diagnosis, depression scores, suicidal ideation or acts, substance abuse, episodes/year, and %-time ill. Results. Scores for cyc ranked: BD-2 > BD-1 > MDD; anx ranked: MDD > BD-2 > BD-1; irr was greater in BD than MDD; dys was greater in MDD than BD; hyp did not differ by diagnosis. We confirmed associations of suicidal risk with higher scores of all temperament types except lower hyp scores. Higher cyc and irr scores and lower anx scores were associated with substance abuse. Several scores were higher with measures of greater affective morbidity: cyc with current depression, episodes/year, and %-time ill; irr with more episodes and depressions/year and greater %-time manic. Some of these associations were selective for BD or MDD. Conclusions. The findings indicate that TEMPS-A ratings of affective temperament types can contribute to differential diagnoses and predict types and amounts of affective morbidity, as well as detecting suicidal risks.

show abstract

Ffective Temperament and Seasonality in Bipolar Disorder

Abstract: Background: Both affective temperaments and seasonality impact on the illness course in bipolar disorder (BD). This exploratory study aims to investigate the link between seasonality and affective temperament in BD.

Cited by 5 publications

References 21 publications

Clinical correlates of seasonality in bipolar disorder: A specifier that needs specification?

Clinical correlates of seasonality in bipolar disorder: A specifier that needs specification?

A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

Relationships of affective temperament ratings to diagnosis and morbidity measures in major affective disorders

Contact Info

Product

Resources

About